<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02155660</url>
  </required_header>
  <id_info>
    <org_study_id>D3251C00004</org_study_id>
    <nct_id>NCT02155660</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History</brief_title>
  <acronym>TERRANOVA</acronym>
  <official_title>A Randomised, Double-blind, Double Dummy, 56 Week Placebo-controlled, Multicentre, Parallel Group, Phase 3 Study Evaluating Efficacy/Safety of 3 Benralizumab Doses in Patients With Moderate to Very Severe COPD With Previous Exacerbations.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine if benralizumab reduces COPD exacerbation rate in
      symptomatic patients with moderate to very severe COPD who are receiving standard of care
      therapies.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 25, 2014</start_date>
  <completion_date type="Actual">April 9, 2018</completion_date>
  <primary_completion_date type="Actual">April 9, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Annual COPD Exacerbation Rate Over 56 Weeks Treatment Comparison for Patients With Baseline EOS&gt;=220/uL</measure>
    <time_frame>Immediately following the first IP dose through week 56</time_frame>
    <description>A COPD exacerbation is defined by symptomatic worsening of COPD requiring:
Use of systemic corticosteroids for at least 3 days; a single depot injectable dose of corticosteroids will be considered equivalent to a 3-day course of systemic corticosteroids; and/or
Use of antibiotics; and/or
An inpatient hospitalization or death due to COPD Annual COPD exacerbation rate is the number of exacerbations per year. Its raw rate is calculated by number of exacerbations divided by the treatment period and then normalized to an annual rate, and is estimated by negative binomial model. Rate ratio between two treatment groups is also estimated through this model.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Annual COPD Exacerbation Rate Over 56 Weeks Treatment Comparison for Patients With Baseline EOS&lt;220/uL</measure>
    <time_frame>Immediately following the first IP dose through week 56</time_frame>
    <description>A COPD exacerbation is defined by symptomatic worsening of COPD requiring:
Use of systemic corticosteroids for at least 3 days; a single depot injectable dose of corticosteroids will be considered equivalent to a 3-day course of systemic corticosteroids; and/or
Use of antibiotics; and/or
An inpatient hospitalization or death due to COPD Annual COPD exacerbation rate is the number of exacerbations per year. Its raw rate is calculated by number of exacerbations divided by the treatment period and then normalized to an annual rate, and is estimated by negative binomial model. Rate ratio between two treatment groups is also estimated through this model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline to Week 56 in Pre-bronchodilator FEV1 (L) Value for Patients With Baseline EOS&gt;=220/uL</measure>
    <time_frame>First IP up to end of treatment Week 56</time_frame>
    <description>Pre-bronchodilator FEV1 (L) is collected at Weeks 0, 4, 8, 16, 24, 32, 40, 48, and 56. Baseline is the last non-missing value with quality (acceptable or borderline quality grade) prior to the first dose of study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in SGRQ Total Score for Patients With Baseline EOS&gt;=220/uL</measure>
    <time_frame>First IP up to Week 56</time_frame>
    <description>SGRQ is from 50-item PRO instrument. The SGRQ total score is expressed as a percentage of overall impairment, in which 100% means the worst possible health status and 0 indicates the best possible health status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in CAT Total Score for Patients With Baseline EOS&gt;=220/uL</measure>
    <time_frame>First IP up to Week 56</time_frame>
    <description>CAT is an 8-item PRO developed to measure the impact of COPD on health status. The instrument uses semantic differential six-point response scales. A CAT total score is the sum of item responses. Score ranges from 0 to 40 with higher scores indicative of greater COPD impact on health status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in E-RS: COPD Total Score for Patients With Baseline EOS&gt;=220/uL</measure>
    <time_frame>First IP up to Week 56</time_frame>
    <description>The E-RS: COPD is an 11-item PRO developed to evaluate the severity of respiratory symptoms of COPD. Summation of E-RS: COPD item responses produces a total score ranging from 0 to 40, with higher scores indicating greater severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Total Rescue Medication Use (Number of Puffs Per Day) for Patients With Baseline EOS&gt;=220/uL</measure>
    <time_frame>First IP up to Week 56</time_frame>
    <description>The number of rescue medication inhalations and nebulizer treatments taken are recorded by the patient in the eDiary twice daily. Total rescue medication use is the sum of daytime and night-time use.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Proportion of Nights With Awakenings Due to Respiratory Symptoms for Patients With Baseline EOS&gt;=220/uL</measure>
    <time_frame>First IP up to Week 56</time_frame>
    <description>Change from baseline to Week 56 in proportion of nights with awakenings due to respiratory symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants by Number of COPD Exacerbations Based on EXACT-PRO for Patients With Baseline EOS&gt;=220/uL</measure>
    <time_frame>Immediately following first IP up to week 56</time_frame>
    <description>The EXACT-PRO is a 14-item PRO instrument developed to assess the frequency, severity and duration of COPD exacerbations. Respondents are instructed to complete the electronic diary (eDiary) each evening just prior to bedtime and to answer the questions while considering their experiences &quot;today&quot;. The daily EXACT-PRO total score is recorded and has a range of 0-100 with higher scores indicative of greater severity. COPD exacerbation event frequency is calculated based on comparison of the baseline score with daily total scores. An increase of EXACT-PRO total score ≥9 for 3 days or ≥12 for 2 days indicates a COPD exacerbation event has occurred.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of EXACT-PRO for Patients With Baseline EOS&gt;=220/uL</measure>
    <time_frame>Immediately following first IP up to week 56</time_frame>
    <description>The EXACT-PRO is a 14-item PRO instrument developed to assess the frequency, severity and duration of COPD exacerbations. Respondents are instructed to complete the electronic diary (eDiary) each evening just prior to bedtime and to answer the questions while considering their experiences &quot;today&quot;. The daily EXACT-PRO total score has a range of 0-100 with higher scores indicative of greater severity. Severity of the study is the highest score of EXACT-PRO.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of COPD Exacerbation Based on EXACT-PRO Score for Patients With Baseline EOS&gt;=220/uL</measure>
    <time_frame>Immediately following first IP up to week 56</time_frame>
    <description>The EXACT-PRO is a 14-item PRO instrument developed to assess the frequency, severity and duration of COPD exacerbations. Respondents are instructed to complete the electronic diary (eDiary) each evening just prior to bedtime and to answer the questions while considering their experiences &quot;today&quot;. The daily EXACT-PRO total score has a range of 0-100 with higher scores indicative of greater severity. COPD exacerbation event frequency is identified by comparing the baseline score with daily total scores. An increase in EXACT-PRO total score ≥9 for 3 days or ≥12 for 2 days indicate an event has occurred. Event duration is calculated after identification of the following five parameters: 1) onset; 2) three-day rolling average; 3) maximum observed value; 4) threshold for improvement; and 5) recovery. That is, duration of the exacerbation is the time elapse between onset and recovery of the event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annual EXACT-PRO Exacerbation Rate Over 56 Weeks Treatment Comparison for Patients With Baseline EOS&gt;=220/uL</measure>
    <time_frame>Immediately following the first IP dose through week 56</time_frame>
    <description>The EXACT-PRO is a 14-item PRO instrument developed to assess the frequency, severity and duration of COPD exacerbations. Respondents are instructed to complete the electronic diary (eDiary) each evening just prior to bedtime and to answer the questions while considering their experiences &quot;today&quot;. The daily EXACT-PRO total score has a range of 0-100 with higher scores indicative of greater severity. Event frequency is calculated by comparing the baseline with daily total scores. An increase in EXACT-PRO total score ≥9 for 3 days or ≥12 for 2 days indicate an event has occurred. Annual EXACT-PRO exacerbation rate is the number of exacerbations per year. Its raw rate is calculated by number of exacerbations divided by the treatment period and then normalized to an annual rate, and is estimated by negative binomial model. Rate ratio between two treatment groups is also estimated through this model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Having at Least 1 COPD Exacerbation for Patients With Baseline EOS&gt;=220/uL</measure>
    <time_frame>Immediately following first IP dose up to week 56</time_frame>
    <description>A COPD exacerbation is defined by symptomatic worsening COPD requiring systemic corticosteroids, antibiotics, or an inpatient hospitalization/death due to COPD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First COPD Exacerbation</measure>
    <time_frame>Immediately following IP dose to Week 56</time_frame>
    <description>Time to first COPD exacerbation is from the randomization date to the first occurrence of COPD exacerbation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annual COPD Exacerbation Rate Associated With ER or Hospitalization Over 56 Weeks Treatment Comparison for Patients With Baseline EOS&gt;=220/uL</measure>
    <time_frame>Immediately following the first IP dose through week 56</time_frame>
    <description>Annual COPD exacerbations rate that result in ER or hospitalization is calculated by number of exacerbations resulting ER or hospitalization divided by the treatment period and then normalized to an annual rate, and is estimated by negative binomial model. Rate ratio between two treatment groups is also estimated through this model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Had COPD-related Healthcare Encounter for Patient With Baseline EOS&gt;=220/uL</measure>
    <time_frame>Immediately following first IP dose up to Week 56</time_frame>
    <description>Types of healthcare encounter: Hospitalisations (inc. intensive care and/or general care), Emergency department visits, Unscheduled outpatients visits, Home visits, Telephone calls, and ambulance transports.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Study Treatment Administration</measure>
    <time_frame>From first dose date to last dose date, 48 weeks per protocol.</time_frame>
    <description>Duration of study treatment is calculated from first dose date to last dose date + 1 day.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Concentration of Benralizumab</measure>
    <time_frame>Pre-first dose and pre-dose at end of treatment (week 56).</time_frame>
    <description>PK serum samples were collected pre-dose at each visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of Benralizumab</measure>
    <time_frame>Pre-treatment until end of follow-up, week 60 per protocol.</time_frame>
    <description>Anti-drug antibody (ADA) responses such as ADA prevalence, ADA incidence, ADA persistently positive counts, etc. were presented.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">2255</enrollment>
  <condition>Moderate to Very Severe Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>Benralizumab Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Benralizumab administered subcutaneously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Benralizumab Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Benralizumab administered subcutaneously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Benralizumab Arm C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Benralizumab administered subcutaneously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered subcutaneously</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Benralizumab Arm A</intervention_name>
    <description>Benralizumab subcutaneously on study week 0 until study week 48 inclusive</description>
    <arm_group_label>Benralizumab Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Benralizumab Arm B</intervention_name>
    <description>Benralizumab subcutaneously on study week 0 until study week 48 inclusive</description>
    <arm_group_label>Benralizumab Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Benralizumab Arm C</intervention_name>
    <description>Benralizumab subcutaneously on study week 0 until study week 48 inclusive</description>
    <arm_group_label>Benralizumab Arm C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Benralizumab subcutaneously on study week 0 until study week 48 inclusive</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:.

          -  Informed consent.

          -  Subjects 40-85 y.o.

          -  Moderate to very severe COPD with Post Bronchodilator (BD) FEV1&gt;20% and ≤65%.

             -≥2 moderate or ≥1 severe COPD exacerbation(s) required treatment or hospitalization
             within 2-52 weeks prior to Visit1.

          -  Modified Medical Research Council (mMRC) score ≥1 at Visit 1.

          -  Treatment with double or triple therapy throughout the year prior to Visit 1, constant
             2 weeks prior to Visit 1.

          -  Tobacco history of ≥10 pack-years.

          -  Women of childbearing potential must use a highly effective form of birth control from
             Visit 1 until 16 weeks after their last dose, and negative serum pregnancy test result
             at Visit 1.

          -  Male subjects who are sexually active must be surgically sterile one year prior to
             Visit 1 or use an adequate method of contraception from the first Investigational
             Product (IP) dose until 16 weeks after their last dose.

          -  Compliance with maintenance therapy during run-in ≥70%.

          -  Blood eosinophils due to subject's stratification and cap for blood eosinophil
             levels.When any eosinophil cohort is full, subjects in the completed cohort will not
             be randomised and will be withdrawn from the study.

        Exclusion criteria:

          -  Clinically important pulmonary disease other than COPD or another diagnosed pulmonary
             or systemic disease associated with elevated peripheral eosinophil counts.

          -  Any disorder or major physical impairment that is not stable by Investigator opinion
             and/or could affect: - subject safety−study findings or their interpretation or
             subject's ability to complete the entire study duration.

          -  Unstable ischemic heart disease, arrhythmia, cardiomyopathy, or other relevant
             cardiovascular disorder that in Investigator's judgment may put the patient at risk or
             negatively affect the study outcome.

          -  Treatment with systemic corticosteroids and/or antibiotics, and/or hospitalization for
             a COPD exacerbation within 2 weeks prior to Visit1 or during the enrolment and run-in
             period.

          -  Acute upper or lower respiratory infection requiring antibiotics within 2 weeks prior
             to Visit1 or during the enrolment and run-in period.

          -  Pneumonia within 8 weeks prior to Visit1 or during the enrolment and run-in period.

          -  Pregnant, breastfeeding, or lactating women.

          -  Risk factors for pneumonia

          -  History of anaphylaxis to any other biologic therapy.

          -  Long term oxygen therapy with signs and/or symptoms of cor pulmonale, right
             ventricular failure.

          -  Use of immunosuppressive medication within 2 weeks prior to Visit1 and/or during the
             enrolment and run-in period.

          -  Receipt of any investigational non-biologic product within 30 days or 5 half-lives
             prior to Visit 1.

          -  Evidence of active tuberculosis (TB) without an appropriate course of treatment.

          -  Lung volume reduction surgery within the 6 months prior to Visit 1. History of partial
             or total lung resection (single lobe or segmentectomy is acceptable).

          -  Asthma as a primary or main diagnosis according to the Global Initiative for Asthma
             (GINA) guidelines or other accepted guidelines.

          -  Previous treatment with benralizumab.

          -  Helminth parasitic infection diagnosed within 24 weeks prior to Visit 1.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bartolome R. Celli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital, Pulmonary Division, 75 Francis Street, PBB Clinics 3, Boston, MA 02115</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gulf Shores</city>
        <state>Alabama</state>
        <zip>36542</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Montgomery</city>
        <state>Alabama</state>
        <zip>36117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Flagstaff</city>
        <state>Arizona</state>
        <zip>86001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Arcadia</city>
        <state>California</state>
        <zip>91007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93721</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92835</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hawaiian Gardens</city>
        <state>California</state>
        <zip>90716</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Huntington Beach</city>
        <state>California</state>
        <zip>92647</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Northridge</city>
        <state>California</state>
        <zip>91324</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Palmdale</city>
        <state>California</state>
        <zip>93551</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Peninsula</city>
        <state>California</state>
        <zip>90505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Placentia</city>
        <state>California</state>
        <zip>92870</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rolling Hills Estates</city>
        <state>California</state>
        <zip>90274</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Westminster</city>
        <state>California</state>
        <zip>92683</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Centennial</city>
        <state>Colorado</state>
        <zip>80112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80907</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chiefland</city>
        <state>Florida</state>
        <zip>32626</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33765</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Coconut Creek</city>
        <state>Florida</state>
        <zip>33066</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>DeBary</city>
        <state>Florida</state>
        <zip>32713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>DeLand</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Doral</city>
        <state>Florida</state>
        <zip>33172</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Edgewater</city>
        <state>Florida</state>
        <zip>32132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Homestead</city>
        <state>Florida</state>
        <zip>33130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kissimmee</city>
        <state>Florida</state>
        <zip>34744</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33147</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33165</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33174</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33186</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Port Charlotte</city>
        <state>Florida</state>
        <zip>33952</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30331</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Blue Ridge</city>
        <state>Georgia</state>
        <zip>30513</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lawrenceville</city>
        <state>Georgia</state>
        <zip>30046</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Woodstock</city>
        <state>Georgia</state>
        <zip>30189</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nampa</city>
        <state>Idaho</state>
        <zip>83687</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Evergreen Park</city>
        <state>Illinois</state>
        <zip>60805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>O'Fallon</city>
        <state>Illinois</state>
        <zip>62269</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>River Forest</city>
        <state>Illinois</state>
        <zip>60305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <zip>66606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Henderson</city>
        <state>Kentucky</state>
        <zip>42420</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Owensboro</city>
        <state>Kentucky</state>
        <zip>42303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Opelousas</city>
        <state>Louisiana</state>
        <zip>70570</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sunset</city>
        <state>Louisiana</state>
        <zip>70584</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bangor</city>
        <state>Maine</state>
        <zip>04401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lutherville</city>
        <state>Maryland</state>
        <zip>21093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>White Marsh</city>
        <state>Maryland</state>
        <zip>21162</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fall River</city>
        <state>Massachusetts</state>
        <zip>02720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Marlborough</city>
        <state>Massachusetts</state>
        <zip>01752</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Buckley</city>
        <state>Michigan</state>
        <zip>49620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <zip>48085</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Edina</city>
        <state>Minnesota</state>
        <zip>55435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fridley</city>
        <state>Minnesota</state>
        <zip>55432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Woodbury</city>
        <state>Minnesota</state>
        <zip>55125</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Picayune</city>
        <state>Mississippi</state>
        <zip>39466</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Port Gibson</city>
        <state>Mississippi</state>
        <zip>39150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Belton</city>
        <state>Missouri</state>
        <zip>64012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Florissant</city>
        <state>Missouri</state>
        <zip>63033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Missoula</city>
        <state>Montana</state>
        <zip>59808</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fremont</city>
        <state>Nebraska</state>
        <zip>68025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89146</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Marlton</city>
        <state>New Jersey</state>
        <zip>08053</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Union</city>
        <state>New Jersey</state>
        <zip>07083</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10459</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>11023</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <zip>11501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New Windsor</city>
        <state>New York</state>
        <zip>12553</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Potsdam</city>
        <state>New York</state>
        <zip>13676</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Burlington</city>
        <state>North Carolina</state>
        <zip>27215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Calabash</city>
        <state>North Carolina</state>
        <zip>28467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28277</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hickory</city>
        <state>North Carolina</state>
        <zip>28601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mooresville</city>
        <state>North Carolina</state>
        <zip>28117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New Bern</city>
        <state>North Carolina</state>
        <zip>28562</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shelby</city>
        <state>North Carolina</state>
        <zip>28150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chardon</city>
        <state>Ohio</state>
        <zip>44024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Marion</city>
        <state>Ohio</state>
        <zip>43302</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43617</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Clackamas</city>
        <state>Oregon</state>
        <zip>97015-6804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <zip>97504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Monroeville</city>
        <state>Pennsylvania</state>
        <zip>15146</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19142</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15243</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Uniontown</city>
        <state>Pennsylvania</state>
        <zip>15401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29412</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hodges</city>
        <state>South Carolina</state>
        <zip>29653</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tullahoma</city>
        <state>Tennessee</state>
        <zip>37388</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Corsicana</city>
        <state>Texas</state>
        <zip>75110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Duncanville</city>
        <state>Texas</state>
        <zip>75116</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77043</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77055</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77063</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>78756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Huntsville</city>
        <state>Texas</state>
        <zip>77340</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Killeen</city>
        <state>Texas</state>
        <zip>76543</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lampasas</city>
        <state>Texas</state>
        <zip>76550</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Longview</city>
        <state>Texas</state>
        <zip>75604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lufkin</city>
        <state>Texas</state>
        <zip>75904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>McKinney</city>
        <state>Texas</state>
        <zip>75069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>McKinney</city>
        <state>Texas</state>
        <zip>75071</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sealy</city>
        <state>Texas</state>
        <zip>77474</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bountiful</city>
        <state>Utah</state>
        <zip>84010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Abingdon</city>
        <state>Virginia</state>
        <zip>24210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Everett</city>
        <state>Washington</state>
        <zip>98208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kingwood</city>
        <state>West Virginia</state>
        <zip>26357</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1414AIF</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Caba</city>
        <zip>1426</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Caba</city>
        <zip>C1056ABJ</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Caba</city>
        <zip>C1425BEN</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Caba</city>
        <zip>C1431FWO</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ciudad Autónoma de Buenos Aire</city>
        <zip>C1440BRR</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ciudad de Buenos Aires</city>
        <zip>1425</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Concepción del Uruguay</city>
        <zip>3260</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Corrientes</city>
        <zip>3400</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Córdoba</city>
        <zip>X5003DCE</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Córdoba</city>
        <zip>X5014KEH</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Florencio Varela</city>
        <zip>1888</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Florida</city>
        <zip>1638</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mar del Plata</city>
        <zip>7600</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mar del Plata</city>
        <zip>B7600GNY</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mendoza</city>
        <zip>5500</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mendoza</city>
        <zip>M5500GIP</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nueve de julio</city>
        <zip>B6500EZL</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Quilmes</city>
        <zip>B1878FNR</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rosario</city>
        <zip>S2000DEJ</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Fernando</city>
        <zip>1646</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Miguel de Tucuman</city>
        <zip>T4000IAR</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Clayton</city>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gosford</city>
        <zip>2250</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Murdoch</city>
        <zip>6150</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nedlands</city>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New Lambton</city>
        <zip>2310</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Woolloongabba</city>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brussels</city>
        <zip>1020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Genk</city>
        <zip>3600</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jambes</city>
        <zip>5100</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Malmedy</city>
        <zip>4960</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Turnhout</city>
        <zip>2300</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Veurne</city>
        <zip>8630</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fortaleza</city>
        <zip>60864190</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Porto Alegre</city>
        <zip>90035-074</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Porto Alegre</city>
        <zip>90470-340</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Porto Alegre</city>
        <zip>90610-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Porto Alegre</city>
        <zip>91350-200</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>22271-100</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santo Andre</city>
        <zip>09080-110</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sao Paulo</city>
        <zip>04020060</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sao Paulo</city>
        <zip>04023-062</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sao Paulo</city>
        <zip>05403-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sorocaba</city>
        <zip>18040-425</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vitória</city>
        <zip>29055-450</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dupnitsa</city>
        <zip>2600</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kozloduy</city>
        <zip>3320</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pazardzhik</city>
        <zip>4400</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pernik</city>
        <zip>2300</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Petrich</city>
        <zip>2850</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Plovdiv</city>
        <zip>4002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ruse</city>
        <zip>7002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sandanski</city>
        <zip>2800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Silistra</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sofia</city>
        <zip>1002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sofia</city>
        <zip>1408</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vidin</city>
        <zip>3700</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vratsa</city>
        <zip>3000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yambol</city>
        <zip>8600</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Curico</city>
        <zip>3341643</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Quillota</city>
        <zip>2260000</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santiago</city>
        <zip>7500698</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santiago</city>
        <zip>7500800</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Talca</city>
        <zip>3465584</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Armenia</city>
        <zip>630004</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barranquilla</city>
        <zip>80001</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bogota</city>
        <zip>111511</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bogotá</city>
        <zip>110221</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bogotá</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cali</city>
        <zip>76001000</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Manizales</city>
        <zip>17001</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Medellin</city>
        <zip>5001000</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Medillin</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Petrinja</city>
        <zip>44250</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Aarhus N</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>København NV</city>
        <zip>2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Næstved</city>
        <zip>4700</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Odense C</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Roskilde</city>
        <zip>4000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Silkeborg</city>
        <zip>8600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bois Guillaume</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brest Cedex</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>La Tronche</city>
        <zip>38700</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lille cedex</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lyon Cedex 04</city>
        <zip>69317</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Marseille</city>
        <zip>13915</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>NIMES Cedex 9</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Orléans Cedex 2</city>
        <zip>45100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Haifa</city>
        <zip>34362</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jerusalem</city>
        <zip>9372212</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Petach Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rehovot</city>
        <zip>7661041</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tel Aviv</city>
        <zip>IL-</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Durango</city>
        <zip>43080</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Guadalajara</city>
        <zip>44130</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Guadalajara</city>
        <zip>44200</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mexico</city>
        <zip>14050</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Monterrey</city>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Monterrey</city>
        <zip>66465</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Auckland</city>
        <zip>0626</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Auckland</city>
        <zip>2025</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dunedin</city>
        <zip>9016</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Greenlane</city>
        <zip>1051</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hamilton West</city>
        <zip>3204</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tauranga</city>
        <zip>3112</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bodø</city>
        <zip>N-8092</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kolbjørnsvik</city>
        <zip>N-4816</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Svelvik</city>
        <zip>3060</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cusco</city>
        <zip>CUSCO 01</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lima</city>
        <zip>15033</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lima</city>
        <zip>41</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lima</city>
        <zip>L27</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lima</city>
        <zip>L41</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lima</city>
        <zip>LIMA 1</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lima</city>
        <zip>LIMA 21</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lima</city>
        <zip>LIMA 31</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lima</city>
        <zip>LIMA 33</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Piura</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Iloilo City</city>
        <zip>5000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lipa City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Manila</city>
        <zip>1000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Quezon City</city>
        <zip>1100</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Quezon City</city>
        <zip>1101</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Quezon City</city>
        <zip>1109</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Białystok</city>
        <zip>15-044</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Białystok</city>
        <zip>15-351</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-231</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gdańsk</city>
        <zip>80-952</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gorzów Wlkp</city>
        <zip>66-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Grodzisk Mazowiecki</city>
        <zip>05-825</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Karczew</city>
        <zip>05-480</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Katowice</city>
        <zip>40-648</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kraków</city>
        <zip>30-901</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ostrowiec Świętokrzyski</city>
        <zip>27-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ostrów Wielkopolski</city>
        <zip>63-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ruda Śląska</city>
        <zip>41-707</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Skierniewice</city>
        <zip>96-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sosnowiec</city>
        <zip>41-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Starachowice</city>
        <zip>27-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Szczecin</city>
        <zip>70-111</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Słupca</city>
        <zip>62-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Trzebnica</city>
        <zip>55-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wrocław</city>
        <zip>51-162</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wrocław</city>
        <zip>53-301</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Żnin</city>
        <zip>88-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Celje</city>
        <zip>3000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Golnik</city>
        <zip>4204</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kamnik</city>
        <zip>1241</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ljubljana</city>
        <zip>1000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Maribor</city>
        <zip>2000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Goteborg</city>
        <zip>405 30</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Göteborg</city>
        <zip>41345</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Helsingborg</city>
        <zip>252 20</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lund</city>
        <zip>221 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Malmo</city>
        <zip>21152</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Stockholm</city>
        <zip>114 46</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Uppsala</city>
        <zip>751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Changhua</city>
        <zip>500</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kaohsiung</city>
        <zip>83301</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New-Taipei</city>
        <zip>22056</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taichung</city>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taichung</city>
        <zip>40705</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taipei</city>
        <zip>112</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bangkoknoi</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10600</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hat Yai</city>
        <zip>90110</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Khon Kaen</city>
        <zip>40002</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Muang,</city>
        <zip>55000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nonthaburi</city>
        <zip>11000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Adana</city>
        <zip>01330</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ankara</city>
        <zip>06280</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bursa</city>
        <zip>16059</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Istanbul</city>
        <zip>34020</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Istanbul</city>
        <zip>34098</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>İstanbul</city>
        <zip>34844</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Izmir</city>
        <zip>35100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Izmir</city>
        <zip>35110</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mersin</city>
        <zip>33343</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cherkasy</city>
        <zip>18009</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chernivtsi</city>
        <zip>58000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chernivtsi</city>
        <zip>58022</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dnipropetrovsk</city>
        <zip>49051</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ivano-Frankivsk</city>
        <zip>76012</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kharkiv</city>
        <zip>61035</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kharkiv</city>
        <zip>61039</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kyiv</city>
        <zip>03680</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kyiv</city>
        <zip>04107</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lutsk</city>
        <zip>43000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lviv</city>
        <zip>79066</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Odesa</city>
        <zip>65025</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vinnytsia</city>
        <zip>21001</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zaporizhzhya</city>
        <zip>69063</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zaporizhzhya</city>
        <zip>69065</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zaporizhzhya</city>
        <zip>69068</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Can Tho</city>
        <zip>900000</zip>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hanoi</city>
        <zip>100000</zip>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ho Chi Minh</city>
        <zip>700000</zip>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>Croatia</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Israel</country>
    <country>Mexico</country>
    <country>New Zealand</country>
    <country>Norway</country>
    <country>Peru</country>
    <country>Philippines</country>
    <country>Poland</country>
    <country>Serbia</country>
    <country>Slovenia</country>
    <country>Sweden</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United States</country>
    <country>Vietnam</country>
  </location_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=2563&amp;filename=D3251C00004%20-%20%20%20Statistical%20Analysis%20Plan_Redacted.pdf</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=2563&amp;filename=Terranova%20CSP%20and%20last%20amendment_Redacted.pdf</url>
    <description>Related Info</description>
  </link>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>May 20, 2014</study_first_submitted>
  <study_first_submitted_qc>June 2, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2014</study_first_posted>
  <results_first_submitted>March 18, 2019</results_first_submitted>
  <results_first_submitted_qc>June 7, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">June 26, 2019</results_first_posted>
  <last_update_submitted>June 7, 2019</last_update_submitted>
  <last_update_submitted_qc>June 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Obstructive Lung Diseases</keyword>
  <keyword>Chronic Obstructive Pulmonary Disease</keyword>
  <keyword>Lung Disease</keyword>
  <keyword>Bronchial Diseases</keyword>
  <keyword>COPD Exacerbation</keyword>
  <keyword>Respiratory Tract Diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Benralizumab</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 6, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/60/NCT02155660/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 11, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/60/NCT02155660/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>2255 patients signed informed consent and were randomized to received treatment with benralizumab 10 mg,30 mg, 100 mg or placebo. One participant was excluded from the analysis. Therefore results are provided for 2254 participants.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Benralizumab 10 mg</title>
          <description>Every 8 weeks administered subcutaneously</description>
        </group>
        <group group_id="P2">
          <title>Benralizumab 30 mg</title>
          <description>Every 8 weeks administered subcutaneously</description>
        </group>
        <group group_id="P3">
          <title>Benralizumab 100 mg</title>
          <description>Every 8 weeks administered subcutaneously</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>Every 8 weeks administered subcutaneously</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="562"/>
                <participants group_id="P2" count="562"/>
                <participants group_id="P3" count="562"/>
                <participants group_id="P4" count="568"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="504"/>
                <participants group_id="P2" count="489"/>
                <participants group_id="P3" count="502"/>
                <participants group_id="P4" count="507"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
                <participants group_id="P2" count="73"/>
                <participants group_id="P3" count="60"/>
                <participants group_id="P4" count="61"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Other Reason</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study-specific withdrawal criteria</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Severe non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="17"/>
                <participants group_id="P4" count="19"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="31"/>
                <participants group_id="P3" count="24"/>
                <participants group_id="P4" count="21"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Benralizumab 10 mg</title>
          <description>Every 8 weeks administered subcutaneously</description>
        </group>
        <group group_id="B2">
          <title>Benralizumab 30 mg</title>
          <description>Every 8 weeks administered subcutaneously</description>
        </group>
        <group group_id="B3">
          <title>Benralizumab 100 mg</title>
          <description>Every 8 weeks administered subcutaneously</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>Every 8 weeks administered subcutaneously</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="562"/>
            <count group_id="B2" value="562"/>
            <count group_id="B3" value="562"/>
            <count group_id="B4" value="568"/>
            <count group_id="B5" value="2254"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>Full analysis set</population>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.7" spread="8.47"/>
                    <measurement group_id="B2" value="65.6" spread="8.61"/>
                    <measurement group_id="B3" value="65.0" spread="8.23"/>
                    <measurement group_id="B4" value="65.3" spread="8.44"/>
                    <measurement group_id="B5" value="65.2" spread="8.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>Full analysis set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="196"/>
                    <measurement group_id="B2" value="194"/>
                    <measurement group_id="B3" value="207"/>
                    <measurement group_id="B4" value="209"/>
                    <measurement group_id="B5" value="806"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="366"/>
                    <measurement group_id="B2" value="368"/>
                    <measurement group_id="B3" value="355"/>
                    <measurement group_id="B4" value="359"/>
                    <measurement group_id="B5" value="1448"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <population>Full analysis set</population>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="441"/>
                    <measurement group_id="B2" value="444"/>
                    <measurement group_id="B3" value="443"/>
                    <measurement group_id="B4" value="446"/>
                    <measurement group_id="B5" value="1774"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="19"/>
                    <measurement group_id="B5" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="67"/>
                    <measurement group_id="B4" value="67"/>
                    <measurement group_id="B5" value="273"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="36"/>
                    <measurement group_id="B4" value="36"/>
                    <measurement group_id="B5" value="152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Annual COPD Exacerbation Rate Over 56 Weeks Treatment Comparison for Patients With Baseline EOS&gt;=220/uL</title>
        <description>A COPD exacerbation is defined by symptomatic worsening of COPD requiring:
Use of systemic corticosteroids for at least 3 days; a single depot injectable dose of corticosteroids will be considered equivalent to a 3-day course of systemic corticosteroids; and/or
Use of antibiotics; and/or
An inpatient hospitalization or death due to COPD Annual COPD exacerbation rate is the number of exacerbations per year. Its raw rate is calculated by number of exacerbations divided by the treatment period and then normalized to an annual rate, and is estimated by negative binomial model. Rate ratio between two treatment groups is also estimated through this model.</description>
        <time_frame>Immediately following the first IP dose through week 56</time_frame>
        <population>Full analysis set, baseline EOS&gt;=220/uL</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 10 mg</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 30 mg</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
          <group group_id="O3">
            <title>Benralizumab 100 mg</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Annual COPD Exacerbation Rate Over 56 Weeks Treatment Comparison for Patients With Baseline EOS&gt;=220/uL</title>
          <description>A COPD exacerbation is defined by symptomatic worsening of COPD requiring:
Use of systemic corticosteroids for at least 3 days; a single depot injectable dose of corticosteroids will be considered equivalent to a 3-day course of systemic corticosteroids; and/or
Use of antibiotics; and/or
An inpatient hospitalization or death due to COPD Annual COPD exacerbation rate is the number of exacerbations per year. Its raw rate is calculated by number of exacerbations divided by the treatment period and then normalized to an annual rate, and is estimated by negative binomial model. Rate ratio between two treatment groups is also estimated through this model.</description>
          <population>Full analysis set, baseline EOS&gt;=220/uL</population>
          <units>Exacerbations per year</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="377"/>
                <count group_id="O2" value="394"/>
                <count group_id="O3" value="386"/>
                <count group_id="O4" value="388"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.99" lower_limit="0.87" upper_limit="1.13"/>
                    <measurement group_id="O2" value="1.21" lower_limit="1.08" upper_limit="1.37"/>
                    <measurement group_id="O3" value="1.09" lower_limit="0.96" upper_limit="1.23"/>
                    <measurement group_id="O4" value="1.17" lower_limit="1.04" upper_limit="1.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0638</p_value>
            <method>Negative binomial</method>
            <method_desc>Model includes treatment group, EOS cohort, region, background therapy, number of exacerbations in the previous year.</method_desc>
            <param_type>Rate ratio</param_type>
            <param_value>0.85</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.71</ci_lower_limit>
            <ci_upper_limit>1.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6575</p_value>
            <method>Negative binomial</method>
            <method_desc>Model includes treatment group, EOS cohort, region, background therapy, number of exacerbations in the previous year.</method_desc>
            <param_type>Rate ratio</param_type>
            <param_value>1.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.88</ci_lower_limit>
            <ci_upper_limit>1.23</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3988</p_value>
            <method>Negative binomial</method>
            <method_desc>Model includes treatment group, EOS cohort, region, background therapy, number of exacerbations in the previous year.</method_desc>
            <param_type>Rate ratio</param_type>
            <param_value>0.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.78</ci_lower_limit>
            <ci_upper_limit>1.10</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Annual COPD Exacerbation Rate Over 56 Weeks Treatment Comparison for Patients With Baseline EOS&lt;220/uL</title>
        <description>A COPD exacerbation is defined by symptomatic worsening of COPD requiring:
Use of systemic corticosteroids for at least 3 days; a single depot injectable dose of corticosteroids will be considered equivalent to a 3-day course of systemic corticosteroids; and/or
Use of antibiotics; and/or
An inpatient hospitalization or death due to COPD Annual COPD exacerbation rate is the number of exacerbations per year. Its raw rate is calculated by number of exacerbations divided by the treatment period and then normalized to an annual rate, and is estimated by negative binomial model. Rate ratio between two treatment groups is also estimated through this model.</description>
        <time_frame>Immediately following the first IP dose through week 56</time_frame>
        <population>Full analysis set, baseline EOS&lt;220/uL</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 10 mg</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 30 mg</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
          <group group_id="O3">
            <title>Benralizumab 100 mg</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Annual COPD Exacerbation Rate Over 56 Weeks Treatment Comparison for Patients With Baseline EOS&lt;220/uL</title>
          <description>A COPD exacerbation is defined by symptomatic worsening of COPD requiring:
Use of systemic corticosteroids for at least 3 days; a single depot injectable dose of corticosteroids will be considered equivalent to a 3-day course of systemic corticosteroids; and/or
Use of antibiotics; and/or
An inpatient hospitalization or death due to COPD Annual COPD exacerbation rate is the number of exacerbations per year. Its raw rate is calculated by number of exacerbations divided by the treatment period and then normalized to an annual rate, and is estimated by negative binomial model. Rate ratio between two treatment groups is also estimated through this model.</description>
          <population>Full analysis set, baseline EOS&lt;220/uL</population>
          <units>Exacerbations per year</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="185"/>
                <count group_id="O2" value="168"/>
                <count group_id="O3" value="176"/>
                <count group_id="O4" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.23" lower_limit="1.03" upper_limit="1.46"/>
                    <measurement group_id="O2" value="1.27" lower_limit="1.05" upper_limit="1.53"/>
                    <measurement group_id="O3" value="1.21" lower_limit="1.00" upper_limit="1.45"/>
                    <measurement group_id="O4" value="1.18" lower_limit="0.98" upper_limit="1.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7564</p_value>
            <method>Negative binomial</method>
            <method_desc>Model includes treatment group, region, background therapy, number of exacerbations in the previous year.</method_desc>
            <param_type>Rate ratio</param_type>
            <param_value>1.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.82</ci_lower_limit>
            <ci_upper_limit>1.32</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5573</p_value>
            <method>Negative binomial</method>
            <method_desc>Model includes treatment group, region, background therapy, number of exacerbations in the previous year.</method_desc>
            <param_type>Rate ratio</param_type>
            <param_value>1.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.84</ci_lower_limit>
            <ci_upper_limit>1.37</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8644</p_value>
            <method>Negative binomial</method>
            <method_desc>Model includes treatment group, region, background therapy, number of exacerbations in the previous year.</method_desc>
            <param_type>Rate ratio</param_type>
            <param_value>1.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.80</ci_lower_limit>
            <ci_upper_limit>1.30</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline to Week 56 in Pre-bronchodilator FEV1 (L) Value for Patients With Baseline EOS&gt;=220/uL</title>
        <description>Pre-bronchodilator FEV1 (L) is collected at Weeks 0, 4, 8, 16, 24, 32, 40, 48, and 56. Baseline is the last non-missing value with quality (acceptable or borderline quality grade) prior to the first dose of study treatment.</description>
        <time_frame>First IP up to end of treatment Week 56</time_frame>
        <population>Full analysis set, baseline EOS&gt;=220/uL</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 10 mg</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 30 mg</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
          <group group_id="O3">
            <title>Benralizumab 100 mg</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to Week 56 in Pre-bronchodilator FEV1 (L) Value for Patients With Baseline EOS&gt;=220/uL</title>
          <description>Pre-bronchodilator FEV1 (L) is collected at Weeks 0, 4, 8, 16, 24, 32, 40, 48, and 56. Baseline is the last non-missing value with quality (acceptable or borderline quality grade) prior to the first dose of study treatment.</description>
          <population>Full analysis set, baseline EOS&gt;=220/uL</population>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="325"/>
                <count group_id="O2" value="322"/>
                <count group_id="O3" value="347"/>
                <count group_id="O4" value="344"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.021" spread="0.346"/>
                    <measurement group_id="O2" value="0.011" spread="0.289"/>
                    <measurement group_id="O3" value="0.033" spread="0.291"/>
                    <measurement group_id="O4" value="0.016" spread="0.292"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5043</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model includes treatment group, baseline FEV1 value, EOS cohort, region, background therapy, visit, and treatment by visit interaction.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.015</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.029</ci_lower_limit>
            <ci_upper_limit>0.059</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7691</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model includes treatment group, baseline FEV1 value, EOS cohort, region, background therapy, visit, and treatment by visit interaction.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.007</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.051</ci_lower_limit>
            <ci_upper_limit>0.037</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3767</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model includes treatment group, baseline FEV1 value, EOS cohort, region, background therapy, visit, and treatment by visit interaction.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.024</ci_lower_limit>
            <ci_upper_limit>0.064</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in SGRQ Total Score for Patients With Baseline EOS&gt;=220/uL</title>
        <description>SGRQ is from 50-item PRO instrument. The SGRQ total score is expressed as a percentage of overall impairment, in which 100% means the worst possible health status and 0 indicates the best possible health status.</description>
        <time_frame>First IP up to Week 56</time_frame>
        <population>Full analysis set, baseline EOS&gt;=220/uL</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 10 mg</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 30 mg</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
          <group group_id="O3">
            <title>Benralizumab 100 mg</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in SGRQ Total Score for Patients With Baseline EOS&gt;=220/uL</title>
          <description>SGRQ is from 50-item PRO instrument. The SGRQ total score is expressed as a percentage of overall impairment, in which 100% means the worst possible health status and 0 indicates the best possible health status.</description>
          <population>Full analysis set, baseline EOS&gt;=220/uL</population>
          <units>Percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="331"/>
                <count group_id="O2" value="329"/>
                <count group_id="O3" value="354"/>
                <count group_id="O4" value="349"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.733" spread="14.996"/>
                    <measurement group_id="O2" value="-8.674" spread="17.910"/>
                    <measurement group_id="O3" value="-7.257" spread="15.989"/>
                    <measurement group_id="O4" value="-6.863" spread="16.344"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3636</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model includes treatment group, baseline SGRQ score, EOS cohort, region, background therapy, visit, and treatment by visit interaction.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.011</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.192</ci_lower_limit>
            <ci_upper_limit>1.171</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2106</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model includes treatment group, baseline SGRQ score, EOS cohort, region, background therapy, visit, and treatment by visit interaction.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.388</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.562</ci_lower_limit>
            <ci_upper_limit>0.786</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5851</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model includes treatment group, baseline SGRQ score, EOS cohort, region, background therapy, visit, and treatment by visit interaction.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.602</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.763</ci_lower_limit>
            <ci_upper_limit>1.560</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in CAT Total Score for Patients With Baseline EOS&gt;=220/uL</title>
        <description>CAT is an 8-item PRO developed to measure the impact of COPD on health status. The instrument uses semantic differential six-point response scales. A CAT total score is the sum of item responses. Score ranges from 0 to 40 with higher scores indicative of greater COPD impact on health status.</description>
        <time_frame>First IP up to Week 56</time_frame>
        <population>Full analysis set, baseline EOS&gt;=220/uL</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 10 mg</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 30 mg</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
          <group group_id="O3">
            <title>Benralizumab 100 mg</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in CAT Total Score for Patients With Baseline EOS&gt;=220/uL</title>
          <description>CAT is an 8-item PRO developed to measure the impact of COPD on health status. The instrument uses semantic differential six-point response scales. A CAT total score is the sum of item responses. Score ranges from 0 to 40 with higher scores indicative of greater COPD impact on health status.</description>
          <population>Full analysis set, baseline EOS&gt;=220/uL</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="332"/>
                <count group_id="O2" value="331"/>
                <count group_id="O3" value="354"/>
                <count group_id="O4" value="350"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.18" spread="6.78"/>
                    <measurement group_id="O2" value="-2.43" spread="7.18"/>
                    <measurement group_id="O3" value="-2.36" spread="6.67"/>
                    <measurement group_id="O4" value="-2.36" spread="6.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8525</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model includes treatment group, baseline CAT total score, EOS cohort, region, background therapy, visit, and treatment by visit interaction.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.82</ci_lower_limit>
            <ci_upper_limit>0.99</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9870</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model includes treatment group, baseline CAT total score, EOS cohort, region, background therapy, visit, and treatment by visit interaction.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.91</ci_lower_limit>
            <ci_upper_limit>0.89</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8204</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model includes treatment group, baseline CAT total score, EOS cohort, region, background therapy, visit, and treatment by visit interaction.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.00</ci_lower_limit>
            <ci_upper_limit>0.79</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in E-RS: COPD Total Score for Patients With Baseline EOS&gt;=220/uL</title>
        <description>The E-RS: COPD is an 11-item PRO developed to evaluate the severity of respiratory symptoms of COPD. Summation of E-RS: COPD item responses produces a total score ranging from 0 to 40, with higher scores indicating greater severity.</description>
        <time_frame>First IP up to Week 56</time_frame>
        <population>Full analysis set, baseline EOS&gt;=220/uL</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 10 mg</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 30 mg</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
          <group group_id="O3">
            <title>Benralizumab 100 mg</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in E-RS: COPD Total Score for Patients With Baseline EOS&gt;=220/uL</title>
          <description>The E-RS: COPD is an 11-item PRO developed to evaluate the severity of respiratory symptoms of COPD. Summation of E-RS: COPD item responses produces a total score ranging from 0 to 40, with higher scores indicating greater severity.</description>
          <population>Full analysis set, baseline EOS&gt;=220/uL</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="316"/>
                <count group_id="O2" value="302"/>
                <count group_id="O3" value="317"/>
                <count group_id="O4" value="325"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.657" spread="5.701"/>
                    <measurement group_id="O2" value="-2.219" spread="6.381"/>
                    <measurement group_id="O3" value="-1.593" spread="5.665"/>
                    <measurement group_id="O4" value="-1.137" spread="5.935"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2636</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model includes treatment group, baseline total score, EOS cohort, region, background therapy, visit, and treatment by visit interaction.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.102</ci_lower_limit>
            <ci_upper_limit>0.301</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4087</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model includes treatment group, baseline total score, EOS cohort, region, background therapy, visit, and treatment by visit interaction.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.296</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.998</ci_lower_limit>
            <ci_upper_limit>0.406</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2336</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model includes treatment group, baseline total score, EOS cohort, region, background therapy, visit, and treatment by visit interaction.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.425</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.125</ci_lower_limit>
            <ci_upper_limit>0.275</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Total Rescue Medication Use (Number of Puffs Per Day) for Patients With Baseline EOS&gt;=220/uL</title>
        <description>The number of rescue medication inhalations and nebulizer treatments taken are recorded by the patient in the eDiary twice daily. Total rescue medication use is the sum of daytime and night-time use.</description>
        <time_frame>First IP up to Week 56</time_frame>
        <population>Full analysis set, baseline EOS&gt;=220/uL</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 10 mg</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 30 mg</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
          <group group_id="O3">
            <title>Benralizumab 100 mg</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Total Rescue Medication Use (Number of Puffs Per Day) for Patients With Baseline EOS&gt;=220/uL</title>
          <description>The number of rescue medication inhalations and nebulizer treatments taken are recorded by the patient in the eDiary twice daily. Total rescue medication use is the sum of daytime and night-time use.</description>
          <population>Full analysis set, baseline EOS&gt;=220/uL</population>
          <units>Puffs/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="305"/>
                <count group_id="O2" value="290"/>
                <count group_id="O3" value="310"/>
                <count group_id="O4" value="314"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.36" spread="3.04"/>
                    <measurement group_id="O2" value="-0.24" spread="3.36"/>
                    <measurement group_id="O3" value="-0.17" spread="3.02"/>
                    <measurement group_id="O4" value="0.23" spread="3.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0012</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model includes treatment group, baseline rescue med. use, EOS cohort, region, background therapy, visit, and treatment by visit interaction.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.642</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.029</ci_lower_limit>
            <ci_upper_limit>-0.254</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0852</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model includes treatment group, baseline rescue med. use, EOS cohort, region, background therapy, visit, and treatment by visit interaction.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.340</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.727</ci_lower_limit>
            <ci_upper_limit>0.047</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0650</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model includes treatment group, baseline rescue med. use, EOS cohort, region, background therapy, visit, and treatment by visit interaction.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.364</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.750</ci_lower_limit>
            <ci_upper_limit>0.023</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Proportion of Nights With Awakenings Due to Respiratory Symptoms for Patients With Baseline EOS&gt;=220/uL</title>
        <description>Change from baseline to Week 56 in proportion of nights with awakenings due to respiratory symptoms.</description>
        <time_frame>First IP up to Week 56</time_frame>
        <population>Full analysis set, baseline EOS&gt;=220/uL</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 10 mg</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 30 mg</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
          <group group_id="O3">
            <title>Benralizumab 100 mg</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Proportion of Nights With Awakenings Due to Respiratory Symptoms for Patients With Baseline EOS&gt;=220/uL</title>
          <description>Change from baseline to Week 56 in proportion of nights with awakenings due to respiratory symptoms.</description>
          <population>Full analysis set, baseline EOS&gt;=220/uL</population>
          <units>Proportion of nights</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="316"/>
                <count group_id="O2" value="298"/>
                <count group_id="O3" value="321"/>
                <count group_id="O4" value="322"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.092" spread="0.297"/>
                    <measurement group_id="O2" value="-0.131" spread="0.332"/>
                    <measurement group_id="O3" value="-0.084" spread="0.334"/>
                    <measurement group_id="O4" value="-0.053" spread="0.345"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0415</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model includes treatment group, baseline prop. of nights awakens., EOS cohort, region, background therapy, visit, and treatment by visit interaction.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.041</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.081</ci_lower_limit>
            <ci_upper_limit>-0.002</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0069</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model includes treatment group, baseline prop. of nights awakens., EOS cohort, region, background therapy, visit, and treatment by visit interaction.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.055</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.094</ci_lower_limit>
            <ci_upper_limit>-0.015</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2008</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model includes treatment group, baseline prop. of nights awakens., EOS cohort, region, background therapy, visit, and treatment by visit interaction.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.026</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.065</ci_lower_limit>
            <ci_upper_limit>0.014</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants by Number of COPD Exacerbations Based on EXACT-PRO for Patients With Baseline EOS&gt;=220/uL</title>
        <description>The EXACT-PRO is a 14-item PRO instrument developed to assess the frequency, severity and duration of COPD exacerbations. Respondents are instructed to complete the electronic diary (eDiary) each evening just prior to bedtime and to answer the questions while considering their experiences &quot;today&quot;. The daily EXACT-PRO total score is recorded and has a range of 0-100 with higher scores indicative of greater severity. COPD exacerbation event frequency is calculated based on comparison of the baseline score with daily total scores. An increase of EXACT-PRO total score ≥9 for 3 days or ≥12 for 2 days indicates a COPD exacerbation event has occurred.</description>
        <time_frame>Immediately following first IP up to week 56</time_frame>
        <population>Full analysis set, EOS&gt;=220/uL</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 10 mg</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 30 mg</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
          <group group_id="O3">
            <title>Benralizumab 100 mg</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants by Number of COPD Exacerbations Based on EXACT-PRO for Patients With Baseline EOS&gt;=220/uL</title>
          <description>The EXACT-PRO is a 14-item PRO instrument developed to assess the frequency, severity and duration of COPD exacerbations. Respondents are instructed to complete the electronic diary (eDiary) each evening just prior to bedtime and to answer the questions while considering their experiences &quot;today&quot;. The daily EXACT-PRO total score is recorded and has a range of 0-100 with higher scores indicative of greater severity. COPD exacerbation event frequency is calculated based on comparison of the baseline score with daily total scores. An increase of EXACT-PRO total score ≥9 for 3 days or ≥12 for 2 days indicates a COPD exacerbation event has occurred.</description>
          <population>Full analysis set, EOS&gt;=220/uL</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="377"/>
                <count group_id="O2" value="394"/>
                <count group_id="O3" value="385"/>
                <count group_id="O4" value="388"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>0</title>
                  <measurement_list>
                    <measurement group_id="O1" value="166"/>
                    <measurement group_id="O2" value="173"/>
                    <measurement group_id="O3" value="162"/>
                    <measurement group_id="O4" value="159"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1</title>
                  <measurement_list>
                    <measurement group_id="O1" value="108"/>
                    <measurement group_id="O2" value="107"/>
                    <measurement group_id="O3" value="113"/>
                    <measurement group_id="O4" value="119"/>
                  </measurement_list>
                </category>
                <category>
                  <title>2</title>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="51"/>
                    <measurement group_id="O3" value="56"/>
                    <measurement group_id="O4" value="46"/>
                  </measurement_list>
                </category>
                <category>
                  <title>3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="25"/>
                    <measurement group_id="O4" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>5</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>6</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>7</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>8</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>9</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>10</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>11</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Severity of EXACT-PRO for Patients With Baseline EOS&gt;=220/uL</title>
        <description>The EXACT-PRO is a 14-item PRO instrument developed to assess the frequency, severity and duration of COPD exacerbations. Respondents are instructed to complete the electronic diary (eDiary) each evening just prior to bedtime and to answer the questions while considering their experiences &quot;today&quot;. The daily EXACT-PRO total score has a range of 0-100 with higher scores indicative of greater severity. Severity of the study is the highest score of EXACT-PRO.</description>
        <time_frame>Immediately following first IP up to week 56</time_frame>
        <population>Full analysis set, baseline EOS&gt;=220/uL</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 10 mg</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 30 mg</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
          <group group_id="O3">
            <title>Benralizumab 100 mg</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Severity of EXACT-PRO for Patients With Baseline EOS&gt;=220/uL</title>
          <description>The EXACT-PRO is a 14-item PRO instrument developed to assess the frequency, severity and duration of COPD exacerbations. Respondents are instructed to complete the electronic diary (eDiary) each evening just prior to bedtime and to answer the questions while considering their experiences &quot;today&quot;. The daily EXACT-PRO total score has a range of 0-100 with higher scores indicative of greater severity. Severity of the study is the highest score of EXACT-PRO.</description>
          <population>Full analysis set, baseline EOS&gt;=220/uL</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="211"/>
                <count group_id="O2" value="221"/>
                <count group_id="O3" value="223"/>
                <count group_id="O4" value="229"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.3" spread="12.30"/>
                    <measurement group_id="O2" value="52.1" spread="11.3"/>
                    <measurement group_id="O3" value="51.2" spread="11.0"/>
                    <measurement group_id="O4" value="51.0" spread="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of COPD Exacerbation Based on EXACT-PRO Score for Patients With Baseline EOS&gt;=220/uL</title>
        <description>The EXACT-PRO is a 14-item PRO instrument developed to assess the frequency, severity and duration of COPD exacerbations. Respondents are instructed to complete the electronic diary (eDiary) each evening just prior to bedtime and to answer the questions while considering their experiences &quot;today&quot;. The daily EXACT-PRO total score has a range of 0-100 with higher scores indicative of greater severity. COPD exacerbation event frequency is identified by comparing the baseline score with daily total scores. An increase in EXACT-PRO total score ≥9 for 3 days or ≥12 for 2 days indicate an event has occurred. Event duration is calculated after identification of the following five parameters: 1) onset; 2) three-day rolling average; 3) maximum observed value; 4) threshold for improvement; and 5) recovery. That is, duration of the exacerbation is the time elapse between onset and recovery of the event.</description>
        <time_frame>Immediately following first IP up to week 56</time_frame>
        <population>Full analysis set, baseline EOS&gt;=220/uL</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 10 mg</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 30 mg</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
          <group group_id="O3">
            <title>Benralizumab 100 mg</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of COPD Exacerbation Based on EXACT-PRO Score for Patients With Baseline EOS&gt;=220/uL</title>
          <description>The EXACT-PRO is a 14-item PRO instrument developed to assess the frequency, severity and duration of COPD exacerbations. Respondents are instructed to complete the electronic diary (eDiary) each evening just prior to bedtime and to answer the questions while considering their experiences &quot;today&quot;. The daily EXACT-PRO total score has a range of 0-100 with higher scores indicative of greater severity. COPD exacerbation event frequency is identified by comparing the baseline score with daily total scores. An increase in EXACT-PRO total score ≥9 for 3 days or ≥12 for 2 days indicate an event has occurred. Event duration is calculated after identification of the following five parameters: 1) onset; 2) three-day rolling average; 3) maximum observed value; 4) threshold for improvement; and 5) recovery. That is, duration of the exacerbation is the time elapse between onset and recovery of the event.</description>
          <population>Full analysis set, baseline EOS&gt;=220/uL</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="211"/>
                <count group_id="O2" value="221"/>
                <count group_id="O3" value="223"/>
                <count group_id="O4" value="229"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110.1" spread="114.0"/>
                    <measurement group_id="O2" value="96.1" spread="109.3"/>
                    <measurement group_id="O3" value="99.8" spread="114.8"/>
                    <measurement group_id="O4" value="99.9" spread="113.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Annual EXACT-PRO Exacerbation Rate Over 56 Weeks Treatment Comparison for Patients With Baseline EOS&gt;=220/uL</title>
        <description>The EXACT-PRO is a 14-item PRO instrument developed to assess the frequency, severity and duration of COPD exacerbations. Respondents are instructed to complete the electronic diary (eDiary) each evening just prior to bedtime and to answer the questions while considering their experiences &quot;today&quot;. The daily EXACT-PRO total score has a range of 0-100 with higher scores indicative of greater severity. Event frequency is calculated by comparing the baseline with daily total scores. An increase in EXACT-PRO total score ≥9 for 3 days or ≥12 for 2 days indicate an event has occurred. Annual EXACT-PRO exacerbation rate is the number of exacerbations per year. Its raw rate is calculated by number of exacerbations divided by the treatment period and then normalized to an annual rate, and is estimated by negative binomial model. Rate ratio between two treatment groups is also estimated through this model.</description>
        <time_frame>Immediately following the first IP dose through week 56</time_frame>
        <population>Full analysis set, baseline EOS&gt;=220/uL</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 10 mg</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 30 mg</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
          <group group_id="O3">
            <title>Benralizumab 100 mg</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Annual EXACT-PRO Exacerbation Rate Over 56 Weeks Treatment Comparison for Patients With Baseline EOS&gt;=220/uL</title>
          <description>The EXACT-PRO is a 14-item PRO instrument developed to assess the frequency, severity and duration of COPD exacerbations. Respondents are instructed to complete the electronic diary (eDiary) each evening just prior to bedtime and to answer the questions while considering their experiences &quot;today&quot;. The daily EXACT-PRO total score has a range of 0-100 with higher scores indicative of greater severity. Event frequency is calculated by comparing the baseline with daily total scores. An increase in EXACT-PRO total score ≥9 for 3 days or ≥12 for 2 days indicate an event has occurred. Annual EXACT-PRO exacerbation rate is the number of exacerbations per year. Its raw rate is calculated by number of exacerbations divided by the treatment period and then normalized to an annual rate, and is estimated by negative binomial model. Rate ratio between two treatment groups is also estimated through this model.</description>
          <population>Full analysis set, baseline EOS&gt;=220/uL</population>
          <units>Exacerbations per year</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="377"/>
                <count group_id="O2" value="394"/>
                <count group_id="O3" value="385"/>
                <count group_id="O4" value="388"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.20" lower_limit="1.05" upper_limit="1.37"/>
                    <measurement group_id="O2" value="1.21" lower_limit="1.06" upper_limit="1.37"/>
                    <measurement group_id="O3" value="1.13" lower_limit="0.99" upper_limit="1.29"/>
                    <measurement group_id="O4" value="1.23" lower_limit="1.08" upper_limit="1.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8158</p_value>
            <method>Negative binomial</method>
            <method_desc>Model includes treatment group, EOS cohort, region, background therapy, number of exacerbations in the previous year.</method_desc>
            <param_type>Rate ratio</param_type>
            <param_value>0.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.81</ci_lower_limit>
            <ci_upper_limit>1.18</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8378</p_value>
            <method>Negative binomial</method>
            <method_desc>Model includes treatment group, EOS cohort, region, background therapy, number of exacerbations in the previous year.</method_desc>
            <param_type>Rate ratio</param_type>
            <param_value>0.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.82</ci_lower_limit>
            <ci_upper_limit>1.18</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3759</p_value>
            <method>Negative binomial</method>
            <method_desc>Model includes treatment group, EOS cohort, region, background therapy, number of exacerbations in the previous year.</method_desc>
            <param_type>Rate ratio</param_type>
            <param_value>0.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.76</ci_lower_limit>
            <ci_upper_limit>1.11</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Having at Least 1 COPD Exacerbation for Patients With Baseline EOS&gt;=220/uL</title>
        <description>A COPD exacerbation is defined by symptomatic worsening COPD requiring systemic corticosteroids, antibiotics, or an inpatient hospitalization/death due to COPD.</description>
        <time_frame>Immediately following first IP dose up to week 56</time_frame>
        <population>Full analysis set, baseline EOS&gt;=220/uL</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 10 mg</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 30 mg</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
          <group group_id="O3">
            <title>Benralizumab 100 mg</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Having at Least 1 COPD Exacerbation for Patients With Baseline EOS&gt;=220/uL</title>
          <description>A COPD exacerbation is defined by symptomatic worsening COPD requiring systemic corticosteroids, antibiotics, or an inpatient hospitalization/death due to COPD.</description>
          <population>Full analysis set, baseline EOS&gt;=220/uL</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="377"/>
                <count group_id="O2" value="394"/>
                <count group_id="O3" value="386"/>
                <count group_id="O4" value="388"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="203"/>
                    <measurement group_id="O2" value="241"/>
                    <measurement group_id="O3" value="214"/>
                    <measurement group_id="O4" value="208"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Proportion of participants with &gt;=1 COPD exacerbation.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9141</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test controlling for EOS cohort, region, and background therapy.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.76</ci_lower_limit>
            <ci_upper_limit>1.36</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Proportion of participants with &gt;=1 COPD exacerbation.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0323</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test controlling for EOS cohort, region, and background therapy.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.39</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.03</ci_lower_limit>
            <ci_upper_limit>1.87</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Proportion of participants with &gt;=1 COPD exacerbation.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5109</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test controlling for EOS cohort, region, and background therapy.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.82</ci_lower_limit>
            <ci_upper_limit>1.48</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First COPD Exacerbation</title>
        <description>Time to first COPD exacerbation is from the randomization date to the first occurrence of COPD exacerbation.</description>
        <time_frame>Immediately following IP dose to Week 56</time_frame>
        <population>Full analysis set, baseline EOS&gt;=220/uL</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 10 mg</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 30 mg</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
          <group group_id="O3">
            <title>Benralizumab 100 mg</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First COPD Exacerbation</title>
          <description>Time to first COPD exacerbation is from the randomization date to the first occurrence of COPD exacerbation.</description>
          <population>Full analysis set, baseline EOS&gt;=220/uL</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="377"/>
                <count group_id="O2" value="394"/>
                <count group_id="O3" value="386"/>
                <count group_id="O4" value="388"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="315" lower_limit="244" upper_limit="380"/>
                    <measurement group_id="O2" value="260" lower_limit="225" upper_limit="291"/>
                    <measurement group_id="O3" value="322" lower_limit="278" upper_limit="373"/>
                    <measurement group_id="O4" value="337" lower_limit="261" upper_limit="400"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Annual COPD Exacerbation Rate Associated With ER or Hospitalization Over 56 Weeks Treatment Comparison for Patients With Baseline EOS&gt;=220/uL</title>
        <description>Annual COPD exacerbations rate that result in ER or hospitalization is calculated by number of exacerbations resulting ER or hospitalization divided by the treatment period and then normalized to an annual rate, and is estimated by negative binomial model. Rate ratio between two treatment groups is also estimated through this model.</description>
        <time_frame>Immediately following the first IP dose through week 56</time_frame>
        <population>Full analysis set, baseline EOS&gt;=220/uL</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 10 mg</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 30 mg</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
          <group group_id="O3">
            <title>Benralizumab 100 mg</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Annual COPD Exacerbation Rate Associated With ER or Hospitalization Over 56 Weeks Treatment Comparison for Patients With Baseline EOS&gt;=220/uL</title>
          <description>Annual COPD exacerbations rate that result in ER or hospitalization is calculated by number of exacerbations resulting ER or hospitalization divided by the treatment period and then normalized to an annual rate, and is estimated by negative binomial model. Rate ratio between two treatment groups is also estimated through this model.</description>
          <population>Full analysis set, baseline EOS&gt;=220/uL</population>
          <units>Exacerbations per year</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="377"/>
                <count group_id="O2" value="394"/>
                <count group_id="O3" value="386"/>
                <count group_id="O4" value="388"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.22" lower_limit="0.17" upper_limit="0.29"/>
                    <measurement group_id="O2" value="0.29" lower_limit="0.23" upper_limit="0.36"/>
                    <measurement group_id="O3" value="0.22" lower_limit="0.17" upper_limit="0.28"/>
                    <measurement group_id="O4" value="0.32" lower_limit="0.26" upper_limit="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0287</p_value>
            <method>Negative binomial</method>
            <method_desc>Model includes treatment group, EOS cohort, region, background therapy, previous year exacerbations associated with hospitalization (Y/N).</method_desc>
            <param_type>Rate ratio</param_type>
            <param_value>0.68</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.49</ci_lower_limit>
            <ci_upper_limit>0.96</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4631</p_value>
            <method>Negative binomial</method>
            <method_desc>Model includes treatment group, EOS cohort, region, background therapy, previous year exacerbations associated with hospitalization (Y/N).</method_desc>
            <param_type>Rate ratio</param_type>
            <param_value>0.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.65</ci_lower_limit>
            <ci_upper_limit>1.22</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0185</p_value>
            <method>Negative binomial</method>
            <method_desc>Model includes treatment group, EOS cohort, region, background therapy, previous year exacerbations associated with hospitalization (Y/N).</method_desc>
            <param_type>Rate ratio</param_type>
            <param_value>0.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.48</ci_lower_limit>
            <ci_upper_limit>0.94</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Had COPD-related Healthcare Encounter for Patient With Baseline EOS&gt;=220/uL</title>
        <description>Types of healthcare encounter: Hospitalisations (inc. intensive care and/or general care), Emergency department visits, Unscheduled outpatients visits, Home visits, Telephone calls, and ambulance transports.</description>
        <time_frame>Immediately following first IP dose up to Week 56</time_frame>
        <population>Full analysis set, baseline EOS&gt;=220/uL</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 10 mg</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 30 mg</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
          <group group_id="O3">
            <title>Benralizumab 100 mg</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Had COPD-related Healthcare Encounter for Patient With Baseline EOS&gt;=220/uL</title>
          <description>Types of healthcare encounter: Hospitalisations (inc. intensive care and/or general care), Emergency department visits, Unscheduled outpatients visits, Home visits, Telephone calls, and ambulance transports.</description>
          <population>Full analysis set, baseline EOS&gt;=220/uL</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="377"/>
                <count group_id="O2" value="394"/>
                <count group_id="O3" value="386"/>
                <count group_id="O4" value="388"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hospitalisations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="67"/>
                    <measurement group_id="O3" value="48"/>
                    <measurement group_id="O4" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emergency department</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="72"/>
                    <measurement group_id="O3" value="58"/>
                    <measurement group_id="O4" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unscheduled outpatient visits</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="208"/>
                    <measurement group_id="O2" value="230"/>
                    <measurement group_id="O3" value="225"/>
                    <measurement group_id="O4" value="211"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Home visits</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Telephone calls</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98"/>
                    <measurement group_id="O2" value="112"/>
                    <measurement group_id="O3" value="109"/>
                    <measurement group_id="O4" value="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ambulance transports</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Study Treatment Administration</title>
        <description>Duration of study treatment is calculated from first dose date to last dose date + 1 day.</description>
        <time_frame>From first dose date to last dose date, 48 weeks per protocol.</time_frame>
        <population>Safety analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 10 mg</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 30 mg</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
          <group group_id="O3">
            <title>Benralizumab 100 mg</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Study Treatment Administration</title>
          <description>Duration of study treatment is calculated from first dose date to last dose date + 1 day.</description>
          <population>Safety analysis set</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="561"/>
                <count group_id="O2" value="563"/>
                <count group_id="O3" value="562"/>
                <count group_id="O4" value="568"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="307.4" spread="80.38"/>
                    <measurement group_id="O2" value="302.2" spread="84.62"/>
                    <measurement group_id="O3" value="303.0" spread="88.48"/>
                    <measurement group_id="O4" value="308.8" spread="78.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Concentration of Benralizumab</title>
        <description>PK serum samples were collected pre-dose at each visit.</description>
        <time_frame>Pre-first dose and pre-dose at end of treatment (week 56).</time_frame>
        <population>PK analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 10 mg</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 30 mg</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
          <group group_id="O3">
            <title>Benralizumab 100 mg</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Concentration of Benralizumab</title>
          <description>PK serum samples were collected pre-dose at each visit.</description>
          <population>PK analysis set</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="558"/>
                <count group_id="O2" value="560"/>
                <count group_id="O3" value="552"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="555"/>
                    <count group_id="O2" value="559"/>
                    <count group_id="O3" value="548"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">&lt;LLOQ (Lower limit of quantification)</measurement>
                    <measurement group_id="O2" value="NA" spread="NA">&lt;LLOQ (Lower limit of quantification)</measurement>
                    <measurement group_id="O3" value="NA" spread="51.95">&lt;LLOQ (Lower limit of quantification)</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 56</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="399"/>
                    <count group_id="O2" value="370"/>
                    <count group_id="O3" value="384"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.51" spread="384.81"/>
                    <measurement group_id="O2" value="222.92" spread="248.24"/>
                    <measurement group_id="O3" value="594.33" spread="321.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunogenicity of Benralizumab</title>
        <description>Anti-drug antibody (ADA) responses such as ADA prevalence, ADA incidence, ADA persistently positive counts, etc. were presented.</description>
        <time_frame>Pre-treatment until end of follow-up, week 60 per protocol.</time_frame>
        <population>Safety analysis set. For each parameter, the number of subjects at risk is to be analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 10 mg</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 30 mg</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
          <group group_id="O3">
            <title>Benralizumab 100 mg</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Immunogenicity of Benralizumab</title>
          <description>Anti-drug antibody (ADA) responses such as ADA prevalence, ADA incidence, ADA persistently positive counts, etc. were presented.</description>
          <population>Safety analysis set. For each parameter, the number of subjects at risk is to be analyzed.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="561"/>
                <count group_id="O2" value="563"/>
                <count group_id="O3" value="562"/>
                <count group_id="O4" value="568"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ADA prevalence</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="561"/>
                    <count group_id="O2" value="563"/>
                    <count group_id="O3" value="562"/>
                    <count group_id="O4" value="568"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                    <measurement group_id="O2" value="52"/>
                    <measurement group_id="O3" value="77"/>
                    <measurement group_id="O4" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ADA incidence</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="554"/>
                    <count group_id="O2" value="554"/>
                    <count group_id="O3" value="542"/>
                    <count group_id="O4" value="555"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="39"/>
                    <measurement group_id="O3" value="65"/>
                    <measurement group_id="O4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Both base/post-baseline positive</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="554"/>
                    <count group_id="O2" value="554"/>
                    <count group_id="O3" value="542"/>
                    <count group_id="O4" value="555"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Only post baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="556"/>
                    <count group_id="O2" value="556"/>
                    <count group_id="O3" value="547"/>
                    <count group_id="O4" value="561"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="38"/>
                    <measurement group_id="O3" value="64"/>
                    <measurement group_id="O4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Only baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="559"/>
                    <count group_id="O2" value="561"/>
                    <count group_id="O3" value="557"/>
                    <count group_id="O4" value="562"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ADA persistently positive</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="554"/>
                    <count group_id="O2" value="554"/>
                    <count group_id="O3" value="542"/>
                    <count group_id="O4" value="555"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="43"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ADA transiently positive</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="554"/>
                    <count group_id="O2" value="554"/>
                    <count group_id="O3" value="542"/>
                    <count group_id="O4" value="555"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="21"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>nAb prevalence</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="561"/>
                    <count group_id="O2" value="563"/>
                    <count group_id="O3" value="562"/>
                    <count group_id="O4" value="568"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="37"/>
                    <measurement group_id="O3" value="59"/>
                    <measurement group_id="O4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>nAb incidence</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="554"/>
                    <count group_id="O2" value="554"/>
                    <count group_id="O3" value="542"/>
                    <count group_id="O4" value="555"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="52"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the time patient signed informed consent throughout the treatment period to the follow-up visit (week 60).</time_frame>
      <desc>Adverse events are presented according to the actual treatment the participants received. One participant randomized to Benra 10 mg was treated with Benra 30 mg, thus this participant is counted in Benra 30 mg group, and hence one less participant in Benra 10 mg, compared with patient flow summary (where participants are summarized per randomized treatment group).</desc>
      <group_list>
        <group group_id="E1">
          <title>Benra 10 mg</title>
          <description>Every 8 weeks administered subcutaneously</description>
        </group>
        <group group_id="E2">
          <title>Benra 30 mg</title>
          <description>Every 8 weeks administered subcutaneously</description>
        </group>
        <group group_id="E3">
          <title>Benra 100 mg</title>
          <description>Every 8 weeks administered subcutaneously</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Every 8 weeks administered subcutaneously</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="561"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="563"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="562"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="144" subjects_at_risk="561"/>
                <counts group_id="E2" subjects_affected="177" subjects_at_risk="563"/>
                <counts group_id="E3" subjects_affected="127" subjects_at_risk="562"/>
                <counts group_id="E4" subjects_affected="158" subjects_at_risk="568"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Disseminated intravascular coagulation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Haemorrhagic anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Polycythaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="568"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="561"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="563"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="562"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="561"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="563"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="562"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="561"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="563"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="562"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="561"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="563"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="562"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Aortic valve incompetence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="561"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="563"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="562"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="561"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Atrioventricular block</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="563"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="562"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="562"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Cardiac failure chronic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="561"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="561"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="563"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="562"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="561"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="563"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Cor pulmonale</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="561"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="561"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="563"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="562"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Right ventricular failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal artery embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal incarcerated hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Chronic gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="563"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Colonic pseudo-obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Diverticular perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Duodenitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Femoral hernia strangulated</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Gastrointestinal polyp haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Incarcerated inguinal hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="562"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Lumbar hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Oesophageal hypomotility</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="561"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Multiple organ dysfunction syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="562"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="568"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="562"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="568"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Food allergy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="561"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="563"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="562"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="563"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="562"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Bronchitis bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Bursitis infective</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Catheter site cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="561"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Diarrhoea infectious</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="561"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="563"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="562"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="562"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Hepatitis C</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="562"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Infectious colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="561"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Intestinal sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Labyrinthitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Lung abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="20" subjects_affected="19" subjects_at_risk="561"/>
                <counts group_id="E2" events="25" subjects_affected="22" subjects_at_risk="563"/>
                <counts group_id="E3" events="10" subjects_affected="9" subjects_at_risk="562"/>
                <counts group_id="E4" events="34" subjects_affected="30" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="561"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="563"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="562"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Pneumonia mycoplasmal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Post procedural infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Pseudomembranous colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Pseudomonas bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Pulmonary sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="563"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="561"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Tracheobronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="561"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="561"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="563"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="562"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="561"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="562"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Abdominal injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Anaemia postoperative</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Carbon monoxide poisoning</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Forearm fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Open fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="562"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Traumatic fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="561"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Traumatic haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Anticoagulation drug level above therapeutic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Electrocardiogram T wave inversion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>False positive tuberculosis test</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>International normalised ratio increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Oxygen saturation decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="568"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Alcohol intolerance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Cachexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Psoriatic arthropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Spondylolisthesis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Trigger finger</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Abdominal neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Acute myeloid leukaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma gastric</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma of colon</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="562"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="561"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="563"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="562"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Brain cancer metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Brain neoplasm benign</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Breast cancer female</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Colon adenoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Colorectal cancer metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Follicular thyroid cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Laryngeal squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Lip and/or oral cavity cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Lung cancer metastatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="561"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="563"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Metastatic malignant melanoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Neuroendocrine carcinoma metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Oesophageal adenocarcinoma stage 0</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Polycythaemia vera</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Renal neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of lung</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of the cervix</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Sweat gland tumour</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Thyroid cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Transitional cell cancer of the renal pelvis and ureter</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid arteriosclerosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Cerebellar haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="561"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="563"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="562"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Cervical myelopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Cognitive disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Dementia Alzheimer's type</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="563"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Hepatic encephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Intercostal neuralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Intracranial aneurysm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="561"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="563"/>
                <counts group_id="E3" events="3" subjects_affected="1" subjects_at_risk="562"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Lumbosacral radiculopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Multiple sclerosis relapse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Myoclonus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Thrombotic cerebral infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="561"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="563"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="562"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Vertebrobasilar insufficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Alcohol abuse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Alcoholism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Bipolar disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Post-traumatic stress disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="562"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Chronic kidney disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="562"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="562"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Renal infarct</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Ureterolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="568"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Acquired hydrocele</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="561"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="563"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="562"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Pelvic prolapse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="561"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="563"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="562"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="129" subjects_affected="92" subjects_at_risk="561"/>
                <counts group_id="E2" events="136" subjects_affected="107" subjects_at_risk="563"/>
                <counts group_id="E3" events="106" subjects_affected="80" subjects_at_risk="562"/>
                <counts group_id="E4" events="140" subjects_affected="89" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Chronic respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="562"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Cystic lung disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="561"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Hypercapnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="561"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Lung infiltration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Pneumothorax spontaneous</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Pulmonary mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="561"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="563"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="562"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="568"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Henoch-Schonlein purpura</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Accelerated hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="561"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="563"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="562"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Aortic dissection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="562"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="563"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Hypovolaemic shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="562"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Penetrating aortic ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="562"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="568"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="251" subjects_at_risk="561"/>
                <counts group_id="E2" subjects_affected="233" subjects_at_risk="563"/>
                <counts group_id="E3" subjects_affected="238" subjects_at_risk="562"/>
                <counts group_id="E4" subjects_affected="260" subjects_at_risk="568"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="17" subjects_affected="15" subjects_at_risk="561"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="563"/>
                <counts group_id="E3" events="18" subjects_affected="17" subjects_at_risk="562"/>
                <counts group_id="E4" events="10" subjects_affected="9" subjects_at_risk="568"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="94" subjects_affected="66" subjects_at_risk="561"/>
                <counts group_id="E2" events="100" subjects_affected="70" subjects_at_risk="563"/>
                <counts group_id="E3" events="87" subjects_affected="63" subjects_at_risk="562"/>
                <counts group_id="E4" events="88" subjects_affected="66" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="561"/>
                <counts group_id="E2" events="22" subjects_affected="20" subjects_at_risk="563"/>
                <counts group_id="E3" events="15" subjects_affected="15" subjects_at_risk="562"/>
                <counts group_id="E4" events="12" subjects_affected="11" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="27" subjects_affected="26" subjects_at_risk="561"/>
                <counts group_id="E2" events="29" subjects_affected="22" subjects_at_risk="563"/>
                <counts group_id="E3" events="16" subjects_affected="15" subjects_at_risk="562"/>
                <counts group_id="E4" events="27" subjects_affected="21" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" events="25" subjects_affected="21" subjects_at_risk="561"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="563"/>
                <counts group_id="E3" events="20" subjects_affected="15" subjects_at_risk="562"/>
                <counts group_id="E4" events="17" subjects_affected="12" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="18" subjects_affected="15" subjects_at_risk="561"/>
                <counts group_id="E2" events="19" subjects_affected="13" subjects_at_risk="563"/>
                <counts group_id="E3" events="21" subjects_affected="15" subjects_at_risk="562"/>
                <counts group_id="E4" events="24" subjects_affected="20" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="109" subjects_affected="68" subjects_at_risk="561"/>
                <counts group_id="E2" events="98" subjects_affected="71" subjects_at_risk="563"/>
                <counts group_id="E3" events="92" subjects_affected="67" subjects_at_risk="562"/>
                <counts group_id="E4" events="89" subjects_affected="65" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="34" subjects_affected="24" subjects_at_risk="561"/>
                <counts group_id="E2" events="26" subjects_affected="24" subjects_at_risk="563"/>
                <counts group_id="E3" events="32" subjects_affected="28" subjects_at_risk="562"/>
                <counts group_id="E4" events="22" subjects_affected="18" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="73" subjects_affected="61" subjects_at_risk="561"/>
                <counts group_id="E2" events="68" subjects_affected="47" subjects_at_risk="563"/>
                <counts group_id="E3" events="92" subjects_affected="60" subjects_at_risk="562"/>
                <counts group_id="E4" events="93" subjects_affected="70" subjects_at_risk="568"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="561"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="563"/>
                <counts group_id="E3" events="20" subjects_affected="17" subjects_at_risk="562"/>
                <counts group_id="E4" events="15" subjects_affected="15" subjects_at_risk="568"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="20" subjects_affected="19" subjects_at_risk="561"/>
                <counts group_id="E2" events="17" subjects_affected="16" subjects_at_risk="563"/>
                <counts group_id="E3" events="34" subjects_affected="27" subjects_at_risk="562"/>
                <counts group_id="E4" events="36" subjects_affected="24" subjects_at_risk="568"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="561"/>
                <counts group_id="E2" events="13" subjects_affected="10" subjects_at_risk="563"/>
                <counts group_id="E3" events="24" subjects_affected="20" subjects_at_risk="562"/>
                <counts group_id="E4" events="34" subjects_affected="24" subjects_at_risk="568"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="22" subjects_affected="17" subjects_at_risk="561"/>
                <counts group_id="E2" events="17" subjects_affected="16" subjects_at_risk="563"/>
                <counts group_id="E3" events="12" subjects_affected="12" subjects_at_risk="562"/>
                <counts group_id="E4" events="22" subjects_affected="21" subjects_at_risk="568"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>≥ 60 days prior to submission of material for publication/presentation, Institution and PI shall jointly provide AZ with material for review. No publication/presentation may include any of AZ’s Confidential Information without AZ’s written approval. AZ can request Inst. and PI to withhold material from submission for publication/presentation for an additional 90 days to allow AZ to establish and preserve its proprietary rights in the material being submitted for publication or presentation.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ulbaldo Martin</name_or_title>
      <organization>AstraZeneca</organization>
      <phone>1.301.398.0163</phone>
      <email>ulbaldo.martin@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

